Amarin Corporation has received the necessary regulatory and ethical approvals to commence a Phase IIa trial in Age Associated Memory Impairment with AMR101.
Ads by Google
Drug Clinical Trials
Sangart has started testing its lead product, Hemospan, in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.
deCODE genetics announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack.
Rigel Pharmaceuticals has begun enrolling patients in a Phase 1 study to evaluate the safety and tolerability of R348, an orally available, potent inhibitor of Janus Kinase 3.
Maxygen announced positive progress in its Phase IIa trial of MAXY-G34 for the treatment of chemotherapy-induced neutropenia.
VIA Pharmaceuticals has enrolled the first patient in its Phase 2 clinical trial that utilizes FDG-PET to measure VIA-2291's ability to reduce vascular inflammation in treated patients.
Surface Logix announced positive results in Phase 2a clinical trial of SLx-2101 in hypertension.
Corthera initiates patient enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute care illnesses.
Nektar Therapeutics starts Phase 2 study for NKTR-118, an oral treatment being developed to treat opioid-induced constipation and other clinical manifestations of opioid-induced bowel dysfunction.
Trius Therapeutics initiated first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections.
22 patients with symptomatic, drug refractory, intermittent AF were followed for a minimum of one year with an average follow-up of eighteen months.
Watson Announces Positive Results From Study Of Oxybutynin Topical Gel For Overactive Bladder Treatment
Watson Pharmaceuticals announced positive results from its Phase 3 study of oxybutynin topical gel (OTG) in patients with overactive bladder.
Pharmasset announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected with hepatitis C virus genotype 1.
The first patient has been treated in Coronado Biosciences's Phase I clinical trial of CNDO101, a rationally designed fourth generation doxorubicin analogue.
Hawaii Biotech has been notified by FDA that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.
Anadys Pharmaceuticals announced preliminary data from two studies of ANA598, a non-nucleoside inhibitor of HCV NS5B polymerase, in a primate model of chronic HCV infection.
Rib-X Pharmaceuticals announced enrolment of the first patients in two separate Phase 2 clinical trials.
The first of two Innocoll's phase 3 clinical trials to investigate CollaRx GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.
Echo Therapeutics has started the second clinical study of its current Symphony Continuous Transdermal Glucose Monitoring System (CTGM System).
MHRA has authorized a Phase 2a clinical trial evaluating RDEA806, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with HIV.
Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.
"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."
Intra-Cellular Therapies has initiated a sleep maintenance insomnia Phase 2 clinical study using its drug candidate ITI-722.
Novavax announced favorable interim results from a Phase I/IIa human clinical trial of its non-adjuvanted pandemic influenza virus-like particle vaccine candidate.
Amicus Therapeutics announced positive results from its recently completed Phase 2 clinical trials of Amigal (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.
Innocoll Initiates Clinical Trial To Investigate CollaRx For Treatment Of Mildly Infected Diabetic Foot Ulcers
Innocoll announced that the first of three planned phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing.
PTC Therapeutics presents preclinical and Phase 1 data regarding PTC299, its novel, internally discovered, vascular endothelial growth factor (VEGF) inhibitor.
SuperGen has dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.
Phosphagenics announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin.
QRxPharma initiatessecond Phase III clinical trial for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.